{"transactions":[{"id":706550,"issuer":{"id":29708,"kind":"organization","name":"CATALYST PHARMACEUTICALS, INC.","symbol":"CPRX"},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-07-17T20:15:57.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with the consummation of the Merger, each reported restricted stock unit (\"RSU\") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger."}],"balance_after":0,"derivative":{"expiration_date":"2028-11-20","underlying":"Common Stock","underlying_shares":5468},"source":{"system":"sec-edgar","filing":"0001161697-26-000172","document":"form_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1369568/000116169726000172/form_4.xml","form_type":"4"}},{"id":706549,"issuer":{"id":29708,"kind":"organization","name":"CATALYST PHARMACEUTICALS, INC.","symbol":"CPRX"},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2026-07-17T20:15:57.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger."}],"balance_after":0,"derivative":{"exercise_price":22.77,"expiration_date":"2032-11-20","underlying":"Common Stock","underlying_shares":18115},"source":{"system":"sec-edgar","filing":"0001161697-26-000172","document":"form_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1369568/000116169726000172/form_4.xml","form_type":"4"}},{"id":706548,"issuer":{"id":29708,"kind":"organization","name":"CATALYST PHARMACEUTICALS, INC.","symbol":"CPRX"},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2026-07-17T20:15:57.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger."}],"balance_after":0,"derivative":{"exercise_price":21.12,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001161697-26-000172","document":"form_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1369568/000116169726000172/form_4.xml","form_type":"4"}},{"id":739022,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:07:08.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5000,"derivative":{"exercise_price":7.99,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-269401","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526269401/ownership.xml","form_type":"4"}},{"id":934336,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-21T21:30:06.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":16833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026."}],"balance_after":16833,"derivative":{"exercise_price":1.32,"expiration_date":"2036-01-19","underlying":"Common Stock","underlying_shares":16833},"source":{"system":"sec-edgar","filing":"0001193125-26-018023","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526018023/ownership.xml","form_type":"4"}},{"id":989742,"issuer":{"id":29708,"kind":"organization","name":"CATALYST PHARMACEUTICALS, INC.","symbol":"CPRX"},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-11-25T01:08:19.000Z","date":"2025-11-20","kind":"grant","planned":false,"acquired":true,"shares":5468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be delivered to the Reporting Person upon vesting."}],"balance_after":63583,"derivative":{"underlying":"Common Stock","underlying_shares":5468},"source":{"system":"sec-edgar","filing":"0001161697-25-000412","document":"form_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1369568/000116169725000412/form_4.xml","form_type":"4"}},{"id":989741,"issuer":{"id":29708,"kind":"organization","name":"CATALYST PHARMACEUTICALS, INC.","symbol":"CPRX"},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options to purchase common stock","published_at":"2025-11-25T01:08:19.000Z","date":"2025-11-20","kind":"grant","planned":false,"acquired":true,"shares":18115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028."}],"balance_after":58115,"derivative":{"exercise_price":22.77,"expiration_date":"2032-11-20","underlying":"Common Stock","underlying_shares":18115},"source":{"system":"sec-edgar","filing":"0001161697-25-000412","document":"form_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1369568/000116169725000412/form_4.xml","form_type":"4"}},{"id":1067868,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-08-13T20:47:50.000Z","date":"2025-08-12","kind":"grant","planned":false,"acquired":true,"shares":40400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 36 equal monthly installments beginning on September 12, 2025."}],"balance_after":40400,"derivative":{"exercise_price":0.615,"expiration_date":"2035-08-11","underlying":"Common Stock","underlying_shares":40400},"source":{"system":"sec-edgar","filing":"0000950170-25-108119","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025108119/ownership.xml","form_type":"4"}},{"id":1112777,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:36:32.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":31000,"derivative":{"exercise_price":0.693,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-016969","document":"form4-06122025_080628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925016969/form4-06122025_080628.xml","form_type":"4"}},{"id":1476766,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":29714,"kind":"person","name":"Curran Daniel J.","position":1,"cik":"0001887599","reported_name":"Curran Daniel J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T20:30:08.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.02,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-017204","document":"form4-06172024_040602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588924017204/form4-06172024_040602.xml","form_type":"4"}}]}